ATNM Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 32.59%. Actinium Pharmaceuticals's return on equity of -95.08% beat Eli Lilly and's return on equity of 80.24%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 287.6%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 36.88%. Given that Actinium Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Actinium Pharmaceuticals is more attractive than Eli Lilly and.

Actinium Pharmaceuticals has a beta of -0.274, which suggesting that the stock is 127.35% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Actinium Pharmaceuticals's net income of -$11.6M is lower than Eli Lilly and's net income of $4.4B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 63.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 14.82x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 23.96%. Actinium Pharmaceuticals's return on equity of -95.08% beat Merck &'s return on equity of 40.25%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 287.6%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 37.56%. Given that Actinium Pharmaceuticals has higher upside potential than Merck &, analysts believe Actinium Pharmaceuticals is more attractive than Merck &.

Actinium Pharmaceuticals has a beta of -0.274, which suggesting that the stock is 127.35% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Merck & quarterly revenues of $15.6B. Actinium Pharmaceuticals's net income of -$11.6M is lower than Merck &'s net income of $3.7B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 3.23x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -49.65%. Actinium Pharmaceuticals's return on equity of -95.08% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 287.6%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 64.47%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.274, which suggesting that the stock is 127.35% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Actinium Pharmaceuticals's net income of -$11.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -2357.27%. Actinium Pharmaceuticals's return on equity of -95.08% beat Palatin Technologies's return on equity of --.

Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 287.6%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that Palatin Technologies has higher upside potential than Actinium Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Actinium Pharmaceuticals.

Actinium Pharmaceuticals has a beta of -0.274, which suggesting that the stock is 127.35% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Palatin Technologies quarterly revenues of $350K. Actinium Pharmaceuticals's net income of -$11.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.